A peptide (EM-1) derived from Asian elephant cathelicidin inhibited herpes simplex virus 1 replication in cells and reduced viral loads in mice by both directly fighting the virus and boosting the host's interferon immune response.
Dual antiviral mechanismEM-1 both directly inhibited HSV-1 replication and enhanced host antiviral immunity by upregulating interferon-gamma and downstream antiviral genes — a two-pronged approach that could reduce resistance risk.
What the researchers found
Four peptides (EM-1 through EM-4) were designed from Asian elephant (Elephas maximus) cathelicidin EM. EM-1 demonstrated the best profile: low hemolytic and cytotoxicity, with significant inhibition of HSV-1 replication in U251 cells.
In C57BL/6J mice infected via footpad inoculation, EM-1 substantially reduced viral loads in brain, lung, and heart tissues and alleviated inflammatory responses and tissue damage. Mechanistically, EM-1 upregulated interferon-gamma expression and downstream antiviral genes ISG15 and MX1, revealing a dual-function profile: direct antiviral activity plus enhancement of host innate immunity.
Why it matters
HSV-1 infects an estimated 3.7 billion people globally, and current antivirals like acyclovir cannot address viral latency or prevent recurrence. New antiviral approaches are urgently needed. Animal-derived antimicrobial peptides represent a largely untapped source of antiviral candidates, and the dual mechanism of EM-1 — directly fighting the virus while boosting immune defenses — is particularly attractive because it could reduce the chance of drug resistance.
How the study worked
Four peptides derived from elephant cathelicidin were designed and optimized. Safety was assessed through hemolytic and cytotoxicity assays. Antiviral activity was measured by IC50 determination against HSV-1 in U251 (human glioma) cells. Mechanisms were investigated using RT-qPCR for gene expression. In vivo validation used C57BL/6J mice with footpad HSV-1 inoculation, measuring viral loads in brain, lung, and heart, plus histological assessment of tissue damage.
What this study cannot tell us
This was a preclinical study using cell lines and mouse models. The mouse footpad HSV-1 model, while established, doesn't fully recapitulate human herpes infection patterns including latency in ganglia and reactivation. IC50 values for EM-1 were not specified in the abstract. The pharmacokinetics, stability, and optimal dosing route for EM-1 in vivo were not characterized. The study used U251 glioma cells rather than more physiologically relevant epithelial cells for in vitro testing.
How to read the evidence
This is a preclinical study with both in vitro and in vivo (mouse) components. The inclusion of animal model validation strengthens the findings beyond cell culture alone, but no human safety or efficacy data exist. The evidence is at the early drug discovery stage.
When this study was published
Published in 2025, this is very recent research. Antimicrobial peptides as antivirals is an active and growing research area, particularly as drug resistance to conventional antivirals becomes more concerning.
The bigger picture
Cathelicidins are a major family of antimicrobial peptides found across vertebrates, with the human version (LL-37) being extensively studied. Elephants are known for their exceptional cancer resistance and robust immune systems, making their immune peptides of particular research interest. This study adds antiviral activity to the growing portfolio of elephant cathelicidin bioactivities and demonstrates that animal-derived peptides can be optimized for human-relevant viral infections.
Questions still open
- Can EM-1 prevent HSV-1 from establishing latency in sensory ganglia, or does it only reduce active viral replication?
- Would EM-1 show activity against HSV-2 and other herpesviruses given the broad-spectrum nature of cathelicidins?
- How does EM-1's antiviral efficacy and safety profile compare to existing antivirals like acyclovir and valacyclovir?
Common questions
Why use elephant immune proteins to fight human viruses?
Could this peptide cure herpes?
Read the original research
Elephant Cathelicidin-Derived Peptides Inhibit Herpes Simplex Virus 1 Infection.
Antibiotics (Basel, Switzerland), 14(7)
Citation
Yisihaer, Haiche; Dong, Peng; Li, Pengpeng; Deng, Enjie; Meng, Rui; Jin, Lin; Li, Guilan. (2025). Elephant Cathelicidin-Derived Peptides Inhibit Herpes Simplex Virus 1 Infection.. Antibiotics (Basel, Switzerland), 14(7). https://doi.org/10.3390/antibiotics14070655